ATC Group: R06AX25 Mizolastine

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of R06AX25 in the ATC hierarchy

Level Code Title
1 R Respiratory system
2 R06 Antihistamines for systemic use
3 R06A Antihistamines for systemic use
4 R06AX Other antihistamines for systemic use
5 R06AX25 Mizolastine

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 10 mg

Active ingredients in R06AX25

Active Ingredient Description
Mizolastine

Mizolastine possesses antihistamine and antiallergic properties due to a specific and selective antagonism of peripheral histamine H1 receptors.

Related product monographs

Title Information Source Document Type  
MIZOLLEN Modified-release tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicines in this ATC group

France (FR)

Germany (DE)

Israel (IL)

Netherlands (NL)

Spain (ES)

Tunisia (TN)

Turkey (TR)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.